GLTO: 8-K · leadership change
Damora Therapeutics announced that Chief Financial Officer Lori Firmani will cease her duties effective May 1, 2026. Subject to the execution of a separation agreement, Ms. Firmani is entitled to severance benefits including a lump sum payment of salary and bonus, a $6,000 health savings account contribution, and full acceleration of her equity awards. Brian Burkavage, the company's current Senior Vice President of Finance, has been appointed to serve as principal financial officer and principal accounting officer effective immediately. Mr. Burkavage brings previous experience from leadership roles at IO Biotech, Passage Bio, and Aclaris Therapeutics.
